Baytril 2.27 %
Injectable Solution for the treatment of diseases associated with bacteria susceptible to enrofloxacin
Baytril 2.27 %
Injectable Solution for the treatment of diseases associated with bacteria susceptible to enrofloxacin
Product description
Baytril 2.27% Antibacterial Injectable Solution has activity against a broad spectrum of Gram negative and Gram positive bacteria in dogs.
Active ingredients
Each ml of injectable solution contains 22.7 mg of enrofloxacin
Inactive Ingredients: 30 mg of n-butyl alcohol, potassium hydroxide for pH adjustment, and water for injection.
Indications for use
Baytril 2.27% Antibacterial Injectable Solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin:
- Clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of Escherichia coli and Staphylococcus aureus; and urinary cystitis associated with susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus aureus.
Administration and dosage
-
Baytril 2.27% Antibacterial Injectable Solution may be used as the initial dose at 2.5 mg/kg.
-
It should be administered intramuscularly (IM) as a single dose, followed by initiation of Baytril Tablet therapy.
-
Baytril 2.27% Antibacterial Injectable Solution may be administered as follows:
Weight of Animal | Baytril Injectable Solution 2.5 mg/kg1 |
---|---|
9.1 kg (20 lb) | 1.00 mL |
27.2 kg (60 lb) | 3.00 mL |
- The lower limit of the dose range was based on efficacy studies in dogs where enrofloxacin was administered at 2.5 mg/kg twice daily. Target animal safety and toxicology studies were used to establish the upper limit of the dose range and treatment duration.
-
The initial Baytril Injectable administration should be followed 12 hours later by initiation of Baytril Tablet therapy. ↩